Ratio Review: Analyzing Opko Health Inc (OPK)’s Price-to-Cash and Price-to-Free Cash Flow

Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.

After finishing at $1.41 in the prior trading day, Opko Health Inc (NASDAQ: OPK) closed at $1.39, down -1.42%. In other words, the price has decreased by -$1.42 from its previous closing price. On the day, 1.74 million shares were traded. OPK stock price reached its highest trading level at $1.43 during the session, while it also had its lowest trading level at $1.39.

Ratios:

Our goal is to gain a better understanding of OPK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.02 and its Current Ratio is at 3.41. In the meantime, Its Debt-to-Equity ratio is 0.31 whereas as Long-Term Debt/Eq ratio is at 0.29.

On June 29, 2023, Barrington Research Upgraded its rating to Outperform which previously was Mkt Perform but kept the price unchanged to $2. On December 15, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $3.H.C. Wainwright initiated its Buy rating on December 15, 2022, with a $3 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 08 ’25 when FROST PHILLIP MD ET AL bought 675,000 shares for $1.32 per share. The transaction valued at 891,000 led to the insider holds 214,676,448 shares of the business.

FROST PHILLIP MD ET AL bought 125,000 shares of OPK for $169,712 on Apr 10 ’25. The CEO & Chairman now owns 214,001,448 shares after completing the transaction at $1.36 per share. On Apr 08 ’25, another insider, FROST PHILLIP MD ET AL, who serves as the CEO & Chairman of the company, bought 125,000 shares for $1.48 each. As a result, the insider paid 184,650 and bolstered with 213,876,448 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OPK now has a Market Capitalization of 1103358336 and an Enterprise Value of 1247693696. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.66 while its Price-to-Book (P/B) ratio in mrq is 0.84. Its current Enterprise Value per Revenue stands at 1.879 whereas that against EBITDA is -7.218.

Stock Price History:

The Beta on a monthly basis for OPK is 1.40, which has changed by -0.15757579 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, OPK has reached a high of $2.04, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is 4.21%, while the 200-Day Moving Average is calculated to be -6.32%.

Shares Statistics:

The stock has traded on average 2.95M shares per day over the past 3-months and 1963960 shares per day over the last 10 days, according to various share statistics. A total of 779.78M shares are outstanding, with a floating share count of 358.25M. Insiders hold about 54.87% of the company’s shares, while institutions hold 27.87% stake in the company. Shares short for OPK as of 1753920000 were 32768192 with a Short Ratio of 11.12, compared to 1751241600 on 34139928. Therefore, it implies a Short% of Shares Outstanding of 32768192 and a Short% of Float of 7.0300005.

Earnings Estimates

At present, 6.0 analysts are actively evaluating the performance of Opko Health Inc (OPK) in the stock market.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.09 and low estimates of -$0.09.

Analysts are recommending an EPS of between -$0.27 and -$0.43 for the fiscal current year, implying an average EPS of -$0.36. EPS for the following year is -$0.35, with 1 analysts recommending between -$0.35 and -$0.35.

Revenue Estimates

5 analysts predict $166.74M in revenue for the current quarter. It ranges from a high estimate of $167.7M to a low estimate of $165.7M. As of the current estimate, Opko Health Inc’s year-ago sales were $173.6MFor the next quarter, 5 analysts are estimating revenue of $168.68M. There is a high estimate of $175.4M for the next quarter, whereas the lowest estimate is $152.5M.

A total of 5 analysts have provided revenue estimates for OPK’s current fiscal year. The highest revenue estimate was $649.8M, while the lowest revenue estimate was $625.76M, resulting in an average revenue estimate of $642.17M. In the same quarter a year ago, actual revenue was $713.1MBased on 6 analysts’ estimates, the company’s revenue will be $637.85M in the next fiscal year. The high estimate is $738.8M and the low estimate is $567.1M.

DWinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.